Co-Commercialization Clause Samples

The co-commercialization clause defines the terms under which two or more parties collaborate to jointly market, sell, and distribute a product or service. Typically, this clause outlines each party’s roles and responsibilities, how costs and revenues will be shared, and the coordination of marketing strategies or sales efforts. By establishing clear guidelines for joint commercial activities, the clause ensures both parties benefit equitably from the partnership and helps prevent disputes over territory, branding, or resource allocation.
Co-Commercialization. Subject to the remainder of this Article 7 and provided Immunocore has not served GNE with a Co-Funding Withdrawal Notice in accordance with Article 8, the Parties shall have co-exclusive rights in, and joint responsibility for, the commercialization of the Licensed Products, in the Field in the Territory; provided, that GNE shall have the sole right to book sales in the Territory.
Co-Commercialization. For clarity, in any Season in which both Parties have been allocated Commercialization activities under the Licensed COVID-19 Mono Product Commercialization Framework in the same country (other than pricing for Licensed Products sold under existing APAs and Settlement Arrangements, provided that for Settlement Arrangements that are not Existing Settlement Arrangements, Novavax shall only have the right to submit confidential tenders, and any non-confidential tenders or other pricing by Novavax, in each case, will require Sanofi’s consent, not to be unreasonably withheld), Sanofi shall have the sole right to determine the market access strategy, including all matters relating to setting prices (including all discounts, rebates, and other similar commercial pricing matters) for all Licensed COVID-19 Mono Products in the Collaboration COVID-19 Territory, including under any Commercial Arrangement.” 1.8 The Parties hereby agree to amend Section 7.3 (Existing APAs and Settlement Arrangements), by deleting that provision and replacing it in its entirety (including its title), as follows:
Co-Commercialization. For the purposes of this Agreement, and specifically this Section 6.3, the terms "Co-Commercialization" and Co-Commercialize" shall mean any and all activity related to the [***] of Collaboration Product(s) sold under GSK's trademark(s) by members of Neurocrine's [***] field sales force where such field sales force members are [***] and otherwise subject to and in accordance with the provisions of this Section 6.3. Subject to the provisions of this Section 6.3, Neurocrine will have an option to Co-commercialize all Collaboration Products [***] (the "Co-Commercialization Option"). Neurocrine may only exercise the Co-Commercialization Option if [***] hereunder, and thereafter, [***] has or will have the [***] and the [***] and [***]. Subject to the foregoing, and notwithstanding that such Co-Commercialization Option [***], such Option can only be, and must be, exercised during the period beginning on the [***] and ending on the [***]. Neurocrine shall then be entitled to provide up to [***] field sales force representatives in the Co-Commercialization of all Collaboration Products. Before commencing Co-Commercialization, [***] shall be entitled to [***] field force representatives first [***]. Thereafter, such Neurocrine field force representatives shall at all times carry out their Co-Commercialization activities (i) under the [***] and (ii) [***]. [***] for Co-Commercialization activities on a [***] basis [***] and the [***] with the [***] of the particular [***] and provided always that the [***] hereunder shall [***] for such [***]. For the avoidance of doubt, [***]. The Parties hereby acknowledge that the foregoing principles may need to be further set out in detail at the time the Co-Commercialization Option is exercised by Neurocrine (and so long as any such new detailed terms do not deviate in any way from such principles).

Related to Co-Commercialization

  • Commercialization Novartis shall have the right to determine whether it is willing to Manufacture Regional Antibody Candidates and Regional Licensed Products for use in Commercialization of such Regional Antibody Candidates and Regional Licensed Products in the Surface Territory and shall communicate such determination by written notice to Surface no later than Initiation of the first Phase 3 Study. If Novartis CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. notifies Surface that it is willing to Manufacture Regional Antibody Candidates and Regional Licensed Products for use in Commercialization in the Surface Territory in accordance with the foregoing, then, Surface may elect, by written notice to Novartis no later than [***] after its receipt of such notice from Novartis whether to utilize Novartis for such Commercial Manufacturing in the Surface Territory or to retain a Third Party contract manufacturer(s) for such purpose. If either Novartis is not willing to provide such Commercial supply (a “Novartis Election”) or Surface elects not to utilize Novartis for such Commercial supply (a “Surface Election”), then Novartis shall effect a technology transfer to a Third Party contract manufacturer(s) to enable such Third Party to provide Commercial supply of Regional Antibody Candidates and Regional Licensed Products for use in the Surface Territory, provided that such Third Party contract manufacturer(s) is approved by Novartis, such approval not to be unreasonably withheld, conditioned or delayed. The cost of such technology transfer shall be borne by (a) Novartis in the case of a Novartis Election; and (b) Surface in the case of either (i) a Surface Election or (ii) any request for a second technology transfer, whether in the case of a Novartis Election or Surface Election; provided, however that Surface may not require of Novartis more than [***] such transfers for any Regional Licensed Product. Further, in the case of a Novartis Election, Novartis shall remain responsible for Manufacturing Commercial supply for use in the Surface Territory until the earlier of (x) such time as the technology transfer is completed or (y) [***] If Novartis is willing to Manufacture Regional Antibody Candidates and Regional Licensed Products for use in Commercialization in the Surface Territory and Surface elects to utilize Novartis for such Commercial Manufacturing in the Surface Territory, the terms of supply of such Regional Antibody Candidates and Regional Licensed Products for use in Commercialization of such Regional Antibody Candidates and Regional Licensed Products in the Surface Territory will be set forth in the RLP Supply Agreement.